TY - JOUR
T1 - Malignant Transformation Rate of Oral Submucous Fibrosis
T2 - A Systematic Review and Meta-Analysis
AU - Murthy, Vignesh
AU - Mylonas, Petros
AU - Carey, Barbara
AU - Yogarajah, Sangeetha
AU - Farnell, Damian
AU - Addison, Owen
AU - Cook, Richard
AU - Escudier, Michael
AU - Diniz-Freitas, Marcio
AU - Limeres, Jacobo
AU - Monteiro, Luis
AU - Silva, Luis
AU - Fricain, Jean Cristophe
AU - Catros, Sylvain
AU - Fenelon, Mathilde
AU - Lodi, Giovanni
AU - Lombardi, Niccolò
AU - Brailo, Vlaho
AU - Ariyaratnam, Raj
AU - López-López, José
AU - Albuquerque, Rui
N1 - Funding Information:
This project is co-funded by the European Union?s Erasmus + Programme ?Oral Potentially Malignant Disorders: Training of Healthcare Professionals?; grant number 2020-1-UK01-KA202-078917. The European Commission support for the production of this publication does not constitute an endorsement of the contents which reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Oral submucous fibrosis (OSF) is a chronic progressive condition affecting the oral cavity, oropharynx and upper third of the oesophagus. It is a potentially malignant disorder. The authors col-lated and analysed the existing literature to establish the overall malignant transformation rate (MTR). A retrospective analysis of medical and dental scientific literature using online indexed databases was conducted for the period 1956 to 2021. The quality of the enrolled studies was assessed by the Newcastle-Ottawa Scale (NOS). A meta-analysis using a random effects model of a single proportion was performed along with statistical tests for heterogeneity. The overall proportion of malignancy across all studies was 0.06 (95% CI, 0.02–0.10), indicating an overall 6% risk of malignant transformation across all studies and cohorts. Sub-group analyses revealed strong differences in proportion of malignancy according to ethnicity/cohort; Chinese = 0.02 (95% CI 0.01–0.02), Taiwanese = 0.06 (95% CI, 0.03–0.10), Indian = 0.08 (95% CI, 0.03–0.14) and Pakistani = 0.27 (95% CI 0.25–0.29). Overall, the MTR was 6%; however, wide heterogeneity of the included studies was noted. Geographic variations in MTR were noted but were not statistically significant. Further studies are required to analyse the difference between cohort groups.
AB - Oral submucous fibrosis (OSF) is a chronic progressive condition affecting the oral cavity, oropharynx and upper third of the oesophagus. It is a potentially malignant disorder. The authors col-lated and analysed the existing literature to establish the overall malignant transformation rate (MTR). A retrospective analysis of medical and dental scientific literature using online indexed databases was conducted for the period 1956 to 2021. The quality of the enrolled studies was assessed by the Newcastle-Ottawa Scale (NOS). A meta-analysis using a random effects model of a single proportion was performed along with statistical tests for heterogeneity. The overall proportion of malignancy across all studies was 0.06 (95% CI, 0.02–0.10), indicating an overall 6% risk of malignant transformation across all studies and cohorts. Sub-group analyses revealed strong differences in proportion of malignancy according to ethnicity/cohort; Chinese = 0.02 (95% CI 0.01–0.02), Taiwanese = 0.06 (95% CI, 0.03–0.10), Indian = 0.08 (95% CI, 0.03–0.14) and Pakistani = 0.27 (95% CI 0.25–0.29). Overall, the MTR was 6%; however, wide heterogeneity of the included studies was noted. Geographic variations in MTR were noted but were not statistically significant. Further studies are required to analyse the difference between cohort groups.
KW - Areca nut
KW - Betel nut
KW - Malignant transformation rate
KW - Oral cancer
KW - Oral potentially malignant disorders
KW - Oral squamous cell carcinoma
KW - Oral submucous fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85126911265&partnerID=8YFLogxK
U2 - 10.3390/jcm11071793
DO - 10.3390/jcm11071793
M3 - Article
AN - SCOPUS:85126911265
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 7
M1 - 1793
ER -